Clinical Trials

62 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04169737 2026-04-14

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

168 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04560322 2026-04-13

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

40 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07029737 2026-04-08

SOUND-MCL

55 enrolled

Lymphoma, Mantle-Cell

NCT04002947 2026-04-06

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

132 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04646395 2026-04-06

Study of Acalabrutinib and Tafasitamab in MZL Patients

26 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT04722172 2026-04-06

A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL

55 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03623373 2026-03-30

Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

13 enrolled 13 charts

Lymphoma, Mantle-Cell

NCT02717611 2026-03-25

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

60 enrolled 11 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05388006 2026-03-25

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

27 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04115631 2026-03-23

A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

360 enrolled

Lymphoma, Mantle-Cell

NCT02180724 2026-03-20

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

107 enrolled 15 charts

Waldenstrom Macroglobulinemia

NCT04624633 2026-02-25

Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL

29 enrolled 9 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05336812 2026-02-19

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

52 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03946878 2026-02-17

Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

32 enrolled

Lymphoma, Mantle-Cell

NCT03580928 2026-02-13

AVO

72 enrolled 12 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02213926 2026-02-10

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

124 enrolled 10 charts 2 FDA

Lymphoma, Mantle-Cell

NCT03516617 2026-02-09

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

120 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04883437 2026-02-09

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

49 enrolled

Lymphoma, Follicular, Lymphoproliferative Disorders, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04624906 2026-02-04

BRAWM

63 enrolled

Waldenstrom Macroglobulinemia

NCT05583149 2026-01-29

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

28 enrolled 6 charts

Phase 2 Not yet recruiting

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

NCT07024706 2026-01-21

MAVRiC

80 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02337829 2026-01-08

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

48 enrolled 12 charts

Chromosome 17 deletion, Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT07014917 2026-01-06

ESR-23-22182

62 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06054776 2026-01-05

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

40 enrolled

Lymphoma, Mantle-Cell

NCT04604067 2025-12-30

Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.

260 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04505254 2025-12-26

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

60 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05952024 2025-12-22

ACRUE

80 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06757647 2025-12-16

Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

61 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05065554 2025-12-05

ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy

12 enrolled

Waldenstrom Macroglobulinemia, Neuritis

NCT04484012 2025-11-26

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

36 enrolled

Lymphoma, Mantle-Cell

NCT06958705 2025-11-25

Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

79 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03128879 2025-11-21

Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

90 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04941716 2025-11-19

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

20 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04765111 2025-11-10

Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

53 enrolled

Lymphoma, Mantle-Cell

NCT04198922 2025-11-05

Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease

Other hematologic neoplasm

51 enrolled

Hematologic Neoplasms

NCT05951959 2025-10-21

TrAVeRse

108 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT06520098 2025-10-14

Benefit VA

100 enrolled

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04546620 2025-08-06

REMoDL-A

453 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04883749 2025-06-08

CLL-Frail

53 enrolled

Leukemia, B-Cell

NCT03863184 2025-06-06

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

37 enrolled 9 charts

Neoplasm, Residual, Lymphoma, Mantle-Cell

NCT06839872 2025-06-05

BOSS

Phase 2 Withdrawn

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06846489 2025-06-03

Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma

50 enrolled

Lymphoma, Mantle-Cell

NCT04189952 2025-05-31

Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma

Phase 2 Terminated

2 enrolled 6 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04685915 2025-05-22

Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL

Phase 2 Withdrawn

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04402138 2025-05-13

Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma

15 enrolled 10 charts

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT04657094 2025-04-27

Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia

Classical hematologyLymphoidOther hematologic neoplasm

4 enrolled 7 charts

Anemia, Hemolytic, Autoimmune, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05004064 2025-04-09

CARAMEL

48 enrolled

Lymphoma, Mantle-Cell

NCT04566887 2025-02-18

Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma

105 enrolled